Inclusion Criteria:

- Patients must be less than 22 years of age at the time of study enrollment.

- Patient must have one of the following:

- Patient has known or suspected relapsed/refractory (including primary refractory) AML;

- This includes isolated myeloid sarcoma.

- Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome.

- Patient has known or suspected relapsed ALL that meets one of the following criteria:

- Second or greater B-ALL medullary relapse, excluding KMT2Ar;

- Any first or greater B-ALL medullary relapse involving KMT2Ar;

- Any first or greater T-ALL medullary relapse with or without KMT2Ar;

- Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia;

- Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML.

- All patients and/or their parents or legal guardians must sign a written informed consent.

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/4/22. Questions regarding updates should be directed to the study team contact.